Showing 1-3 of 3

Sorted By:

  • Prostate Cancer: A031201 (Hematology Oncology Associates)

    The purpose of this study is to compare the effects, good and/or bad, of abiraterone, prednisone, and enzalutamide with enzalutamide alone on patients that have prostate cancer that has spread and has not responded to hormonal therapy to find out which is better.

  • Prostate Cancer: C90203 (Iowa Cancer Specialists)

    The purpose of this study is to compare the effects (good and bad) of the combination of chemotherapy and hormone therapy followed by radical prostatectomy (surgery to remove your prostate) with radical prostatectomy alone on patients with prostate cancer at high-risk of cancer recurrence after surgery to see which is better. The usual approach for treating prostate cancer is surgery alone.

  • Prostate Cancer: S1216 (Hematology Oncology Associates)

    The purpose of this study is to find out what effects (good and/or bad) there are to adding the new investigational drug TAK-700 (also called orteronel) to standard hormone therapy which is used to treat prostate cancer as compared to the standard of hormone therapy alone.

Page InfoPage
Showing trials 1-3 of 3

View Additional Section Content

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email